Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on novel cancer therapies that target nuclear export dysregulation. Its lead product, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. in multiple oncology indications and in various indications across more than 50 ex-U.S. territories and countries, according to company statements.
This news page aggregates company-issued updates and market disclosures related to Karyopharm. Readers can follow announcements on XPOVIO commercial performance, such as reported U.S. net product revenue and trends in license and royalty revenue from international partners, as described in the company’s earnings releases. The feed also covers progress in Karyopharm’s clinical pipeline, including multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL).
Recent news has highlighted key milestones in late-stage development, including completion of enrollment in the Phase 3 SENTRY trial (XPORT-MF-034) in myelofibrosis and ongoing enrollment in the global Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer. Company releases also describe Phase 2 data in heavily pretreated myelofibrosis patients and the design of additional studies such as SENTRY-2 and XPORT-MM-031 in multiple myeloma.
In addition to clinical and commercial updates, Karyopharm’s news includes financial results, preliminary revenue disclosures, strategic financing transactions involving term loans and convertible notes, and inducement equity awards granted under its inducement stock incentive plan. Investors and observers can use this page to review the company’s own descriptions of its operational progress, financing activities and anticipated clinical catalysts as reported in press releases and referenced in SEC filings.
Karyopharm Therapeutics (KPTI) reported positive Phase I/II results for eltanexor, a treatment for hypomethylating agent refractory myelodysplastic syndrome (MDS), during the ASCO Annual Meeting. Out of 15 evaluable patients, 47% achieved marrow complete response (mCR), and the total disease control rate was 80%. Notably, patients with mCR had a median overall survival (mOS) of 11.86 months, compared to 8.67 months for those without mCR. Eltanexor may offer a more tolerable option compared to first-generation inhibitors, with trials ongoing in Asia Pacific markets.
Karyopharm Therapeutics (Nasdaq: KPTI) announced significant management changes aimed at enhancing its commercial operations, including the appointment of Sohanya Cheng as Senior Vice President of Sales and Commercial Operations. Payman Darouian will oversee marketing for the company's lead product, XPOVIO (selinexor), while former executives John Demaree and Perry Monaco will leave to pursue other opportunities. Cheng, with 17 years in biopharmaceuticals, previously led marketing at Arrowhead Pharmaceuticals and has extensive oncology experience, contributing to the company's strategy for multiple myeloma and lymphoma.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the commercial availability of three new strength tablets for XPOVIO, following FDA approval on April 15, 2021. The new strengths of 40 mg, 50 mg, and 60 mg supplement the existing 20 mg tablet, enhancing patient compliance and treatment flexibility. XPOVIO is a first-in-class oral Selective Inhibitor of Nuclear Export (SINE) approved for multiple myeloma and diffuse large B-cell lymphoma. The new strengths do not alter the drug's efficacy or safety profile.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on June 2, 2021, that the UK's Medicines & Healthcare Products Regulatory Agency granted conditional marketing authorization for NEXPOVIO® (selinexor) in combination with dexamethasone to treat multiple myeloma in adult patients who have undergone at least four prior therapies. This authorization is based on positive results from the Phase 2b STORM study, which reported a 26% overall response rate in heavily pretreated patients. Continued authorization will depend on confirming clinical benefits in further trials.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on June 1, 2021, the grant of stock options totaling 24,600 shares to six newly-hired employees as an inducement related to their employment. The options were granted at an exercise price of $9.28 per share, equal to KPTI's closing stock price on May 28, 2021. Each option will vest over four years, with the first 25% vesting on the one-year anniversary of employment. If a 'change in control event' occurs, options may become immediately exercisable upon certain termination conditions.
On May 26, 2021, Karyopharm Therapeutics (Nasdaq: KPTI) announced that CEO Richard Paulson will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference. The event is scheduled for June 2, 2021, at 9:30 a.m. ET. A live webcast can be accessed through the Investor section of the company's website, with a replay available for 30 days post-event. Karyopharm focuses on pioneering novel cancer therapies, including its lead compound XPOVIO® (selinexor), approved for multiple hematologic malignancies in the U.S. and Europe.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the selection of sixteen abstracts for virtual presentation at the ASCO Annual Meeting from June 4-8, 2021. Key highlights include clinical data on XPOVIO® (selinexor) from pivotal studies, showcasing its efficacy in treating multiple myeloma and other cancers. The presentations feature subgroup analyses from the Phase 3 BOSTON study and updates from various combination studies, emphasizing the potential of XPOVIO in overcoming treatment resistance.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the grant of stock options for 55,300 shares to seven new employees as an inducement for joining the company. The options have an exercise price of $9.34, based on the stock's closing price on April 30, 2021. Each option vests over four years, with the first 25% vesting after one year. These options may be fully exercised if employment is terminated for 'good reason' or without 'cause' within one year of a change in control event. Karyopharm focuses on developing novel cancer therapies, including its lead drug, XPOVIO®.
Karyopharm Therapeutics (Nasdaq: KPTI) reported first-quarter 2021 results, showing a net product revenue of $21.7 million, up 35% year-over-year. The company highlighted a leadership transition with Richard Paulson appointed as the new CEO. The ongoing U.S. commercialization of XPOVIO reflects a significant increase in prescription demand, with approximately 1,170 prescriptions filled, marking a 17% increase from Q4 2020. Karyopharm anticipates top-line data from the Phase 3 SIENDO study by year-end and expects a decision from the European Commission on NEXPOVIO in Q4 2021.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) appointed Richard Paulson as President and Chief Executive Officer effective May 3, 2021, succeeding Michael G. Kauffman and Sharon Shacham. Paulson, who has extensive biopharmaceutical experience and previously served as CEO of Ipsen North America, aims to enhance Karyopharm's commercialization efforts and expand the reach of its lead product, XPOVIO. Kauffman transitions to Senior Clinical Advisor, focusing on clinical developments. The leadership change is positioned as essential for driving growth and innovation at a pivotal moment for the company.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
